Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Update: Lineage Cell Therapeutics Q2 Adj. EPS $(0.07) Misses $(0.03) Estimate, Sales $2.765M Beat $1.472M Estimate

Author: Benzinga Newsdesk | August 12, 2025 03:04pm
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.03) by 159.26 percent. This is a 133.33 percent decrease over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $2.765 million which beat the analyst consensus estimate of $1.472 million by 87.80 percent. This is a 96.38 percent increase over sales of $1.408 million the same period last year.

Posted In: LCTX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist